Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share

IBER.WS

IBER.WS Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q2 2023, worth a combined $0 — down 100% from $108K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of IBER.WS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Lynwood Capital Management, exiting entirely with an estimated $108K sold.

• 0 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q2 2023, down from 1 in Q1 2023.
• Funds reported $0 of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q2 2023, down 100% quarter-over-quarter.
• 0 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q2 2023 and 1 closed out, a net change of -1 holder.
• The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q2 2023 was Lynwood Capital Management, an estimated $108K sold.

Based on aggregated 13F filings for Q2 2023.